Catalent will create a new drug development center of excellence

| By | Drug Development, Investments

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced it plans to invest $5 million in the creation of a new drug development center of excellence (CoE) at its Somerset, New Jersey facility and headquarters.

The investment will see the site focus on preclinical to clinical phase 2b formulation, analytical, and manufacturing solutions for orally delivered small molecules. It will also build upon the site’s expertise in the development of modified release formulation, bioavailability solutions, the application of OptiMelt® hot melt extrusion (HME) technology, and its status as the company’s CoE for handling potent compounds and controlled substances.

Catalent’s headquarters and development center in Somerset has a long track record of successfully developing, launching, and manufacturing many oral treatments for leading global innovators. The site boasts state-of-the-art analytical labs, pilot and clinical scale equipment including HME and fluid bed processing, and significant expertise in coating technologies, capsules, tablets, minitablets, and multi-particulates.

Catalent’s early phase drug development sites are closely connected to Catalent’s Clinical Supply Services network, to optimize transition from finished dose manufacture to clinical packaging and distribution. Additionally, the Somerset facility will offer seamless transfers to Catalent’s integrated commercial manufacturing network in: Kansas City, Missouri; Winchester, Kentucky; Swindon, U.K.; and Schorndorf, Germany, for later stage clinical trials using compatible, scalable equipment.

SOURCE: catalent
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.